Distribution fees for the Covid-19 vaccines helped Beximco Pharmaceuticals attain a 41% year-on-year profit jump in the first half of the ongoing fiscal year 2021-22.
The drug maker's profit stood at Tk313 crore in six months, against Tk222 crore during the same period of the last fiscal.
The income of the company increased predominantly for incomes from vaccine distribution fees, which was not there in the period being compared with, the company said in its unaudited financial report.
From vaccine distribution fees, Beximco Pharma earned around Tk61.92 crore in the six-month period.
These have contributed towards an increase in consolidated earnings per share, said the financial report.
Consolidated operating cash flow per share also increased due to the higher revenue and improved net working capital.
The company achieved over 17% growth year-on-year in consolidated sales as it logged sales of Tk1,696 crore in the latest half yearly.
The transfer of ownership of Sanofi Bangladesh was completed on September 30, 2021 for Tk469.6 crore, according to the financial report.
Sanofi Bangladesh was not included in the Beximco Pharma financials.